Drugs / SEA-CD70
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04227847 | Aug 2020 → Jul 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEA-CD70 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04227847 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle” NCT04227847 ↗ |